Synergistic Co-Targeting of BTK and BCL2 in Mantle Cell Lymphoma

被引：1
|
作者：
Li, Yangguang [1 ]
Bouchlaka, Myriam N. [2 ,3 ]
Grindle, Kreg [1 ]
Kahl, Brad S. [4 ]
Miyamoto, Shigeki [5 ]
Yang, David T. [6 ]
Capitini, Christian M. [7 ]
Rui, Lixin [8 ,9 ]
机构：
[1] Dept Med, Madison, WI USA
[2] Univ Madison, Dept Pediat, Madison, WI USA
[3] Univ Madison, Carbone Canc Ctr, Madison, WI USA
[4] Washington Univ, St Louis, MO USA
[5] Dept Oncol, Madison, WI USA
[6] Carbone Canc Ctr, Madison, WI USA
[7] Univ Wisconsin, Dept Pediat, Madison, WI USA
[8] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA
[9] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, Madison, WI USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] BCL2 mutations in diffuse large B-cell lymphoma
    J M Schuetz
    N A Johnson
    R D Morin
    D W Scott
    K Tan
    S Ben-Nierah
    M Boyle
    G W Slack
    M A Marra
    J M Connors
    A R Brooks-Wilson
    R D Gascoyne
    Leukemia, 2012, 26 : 1383 - 1390
  • [42] Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
    Plotnik, Joshua P.
    Richardson, Adam E.
    Yang, Haopeng
    Rojas, Estela
    Bontcheva, Velitchka
    Dowell, Colleen
    Parsons, Sydney
    Wilson, Ashley
    Ravanmehr, Vida
    Will, Christine
    Jung, Paul
    Zhu, Haizhong
    Partha, Sarathy Karunan
    Panchal, Sanjay C.
    Mali, Raghuveer Singh
    Kohlhapp, Frederick J.
    Mcclure, Ryan A.
    Ramathal, Cyril Y.
    George, Mariam D.
    Jhala, Manisha
    Elsen, Nathaniel L.
    Qiu, Wei
    Judge, Russell A.
    Pan, Chin
    Mastracchio, Anthony
    Henderson, Jared
    Meulbroek, Jonathan A.
    Green, Michael R.
    Pappano, William N.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (07) : 949 - 960
  • [43] Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
    Burkart, Madelyn
    Karmali, Reem
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (03):
  • [44] Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
    Liu, Lin
    Mo, Wenbin
    Chen, Miao
    Qu, Yi
    Wang, Pingping
    Liang, Ying
    Yan, Xiaojing
    BMC CANCER, 2024, 24 (01)
  • [45] BTK Inhibition and Response Prediction in Mantle Cell Lymphoma Cells
    Ma, J.
    Guo, A.
    Cheng, S.
    Lu, P.
    Martin, P.
    Furman, R. R.
    Coleman, M.
    Wang, L. Y.
    LABORATORY INVESTIGATION, 2013, 93 : 343A - 343A
  • [46] BTK Inhibition and Response Prediction in Mantle Cell Lymphoma Cells
    Ma, J.
    Guo, A.
    Cheng, S.
    Lu, P.
    Martin, P.
    Furman, R. R.
    Coleman, M.
    Wang, L. Y.
    MODERN PATHOLOGY, 2013, 26 : 343A - 343A
  • [47] BCL2 in follicular lymphoma: the overrated guy?
    Magnoli, F.
    Amaglio, C.
    Marchiori, D.
    Vivian, L. F.
    Martin, V.
    Sessa, F.
    Tibiletti, M. G.
    Uccella, S.
    VIRCHOWS ARCHIV, 2019, 475 : S116 - S117
  • [48] Detection of BCL2 rearrangements in follicular lymphoma
    Aster, JC
    Longtine, JA
    AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (03): : 759 - 763
  • [49] BCL2 inhibition in double hit lymphoma
    Anderson, Mary Ann
    Huang, David C. S.
    Roberts, Andrew W.
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 1928 - 1929
  • [50] Targeting BCL2 for the Treatment of Lymphoid Malignancies
    Anderson, Mary Ann
    Huang, David
    Roberts, Andrew
    SEMINARS IN HEMATOLOGY, 2014, 51 (03) : 219 - 227
12345